Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2017

01-02-2017 | Therapeutic Aspects in Autoimmunity

Glaucoma: recent advances in the involvement of autoimmunity

Authors: Maria Ida Rizzo, Antonio Greco, Armando De Virgilio, Andrea Gallo, Luciano Taverniti, Massimo Fusconi, Michela Conte, Giulio Pagliuca, Rosaria Turchetta, Marco de Vincentiis

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

Glaucomatous optic neuropathy is the most commonly acquired optic neuropathy encountered in clinical practice. It is the second leading cause of blindness globally, after cataracts, but it presents a greater public health challenge than cataracts, because the blindness it causes is irreversible. It has pathogenesis still largely unknown and no established cure. Alterations in serum antibody profiles, upregulation, and downregulation have been described, but it still remains elusive if the autoantibodies seen in glaucoma are an epiphenomenon or causative. Hypertension, diabetes, and hearing disorders also are associated. This review is a glaucoma update with focus about the recent advances in the last 15 years.
Literature
1.
2.
Wax MB, Tezel G, Saito I, et al. Anti-Ro/SS-a positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol. 1998;125:145–57.CrossRefPubMed
3.
4.
Rieck J. The pathogenesis of glaucoma in the interplay with the immune system. Invest Ophthalmol Vis Sci. 2013;54:2393–409.CrossRefPubMed
5.
Kremmer S, Kreuzfelder E, Bachor E, Jahnke K, Selbach JM, Seidahmadi S. Coincidence of normal tension glaucoma, progressive sensorineural hearing loss, and elevated antiphosphatidylserine antibodies. Br J Ophthalmol. 2004;88:1259–62.CrossRefPubMedPubMedCentral
6.
Kremmer S, Anastassiou G, Selbach JM. Hearing disorders with glaucoma. Klin Monbl Augenheilkd. 2014;231:144–50.CrossRefPubMed
7.
8.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.CrossRefPubMed
9.
Javitt JC, McBean AM, Nicholson GA, Babish JD, Warren JL, Krakauer H. Undertreatment of glaucoma among black Americans. N Engl J Med. 1991;325:1418–22.CrossRefPubMed
10.
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.PubMedPubMedCentral
11.
Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–8.CrossRefPubMed
12.
13.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefPubMed
14.
Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–20.CrossRefPubMed
15.
Aung T, Ocaka L, Ebenezer ND, et al. A major marker for normal tension glaucoma: association with polymorphisms in the OPA1 gene. Hum Genet. 2002;110:52–6.CrossRefPubMed
16.
Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population: the Egna-Neumarkt study. Ophthalmology. 1998;105:209–15.CrossRefPubMed
17.
Grus FH, Joachim SC, Pfeiffer N. Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Proteomics. 2003;3:957–61.CrossRefPubMed
18.
19.
Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect. 2006;19:151–8.CrossRefPubMed
20.
Henderson PA, Medeiros FA, Zangwill LM, Weinreb RN. Relationship between central corneal thickness and retinal nerve fiber layer thickness in ocular hypertensive patients. Ophthalmology. 2005;112:251–6.CrossRefPubMed
21.
Maruyama I, Ikeda Y, Nakazawa M, Ohguro H. Clinical roles of serum autoantibody against neuron-specific enolase in glaucoma patients. Tohoku J Exp Med. 2002;197:125–32.CrossRefPubMed
22.
Maruyama I, Ohguro H, Ikeda Y. Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Invest Ophthalmol Vis Sci. 2000;41:1657–65.PubMed
23.
Nickells RW, Howell GR, Soto I, John SW. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci. 2012;35:153–79.CrossRefPubMed
24.
25.
Whitmore AV, Libby RT, John SWM. Glaucoma: thinking in new ways—a rôle for autonomous axonal self-destruction and other compartmentalised processes? Prog Retin Eye Res. 2005;24:639–62.CrossRefPubMed
26.
27.
Bjerrum J. Om en tilføjelse til den sædvanlige synsfelt – undersögelse samt om synsfeltet ved glaukom. Nord ophthal Tidsskrift. 1889;2:141–85.
28.
Nickells RW. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J Glaucoma. 1996;5:345–56.CrossRefPubMed
29.
30.
Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:764–74.PubMed
31.
Agar A, Li S, Agarwal N, Coroneo MT, Hill MA. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res. 2006;1086:191–200.CrossRefPubMed
32.
Agar A, Yip SS, Hill MA, Coroneo MT. Pressure related apoptosis in neuronal cell lines. J Neurosci Res. 2000;60:495–503.CrossRefPubMed
33.
Pfeiffer N. Results of the “Ocular Hypertension treatment study”. Ophthalmologe. 2005;102:230–4.CrossRefPubMed
34.
Nickells RW. The molecular biology of retinal ganglion cell death: caveats and controversies. Brain Res Bull. 2004;62:439–46.CrossRefPubMed
35.
Li Y, Schlamp CL, Poulsen KP, Nickells RW. Bax-dependent and independent pathways of retinal ganglion cell death induced by different damaging stimuli. Exp Eye Res. 2000;71:209–13.CrossRefPubMed
36.
Li Y, Schlamp CL, Poulsen GL, Jackson MW, Griep AE, Nickells RW. p53 regulates apoptotic retinal ganglion cell death induced by N-methyl-d-aspartate. Mol Vis. 2002;8:341–50.PubMed
37.
Wax MB, Tezel G, Yang J, et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived Fas-ligand. J Neurosci. 2008;28:12085–96.CrossRefPubMedPubMedCentral
38.
Nickells RW. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol. 2007;42:278–87.CrossRefPubMed
39.
Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67:725–59.CrossRefPubMed
40.
Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am. 2005;18:383–95.CrossRefPubMed
41.
Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol. 2003;48:S38–46.CrossRefPubMed
42.
Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA. 2001;98:3398–403.CrossRefPubMedPubMedCentral
43.
Vorwerk CK, Naskar R, Schuettauf F, et al. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci. 2000;41:3615–21.PubMed
44.
Honkanen RA, Baruah S, Zimmerman MB, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol. 2003;121:183–8.CrossRefPubMed
45.
Ullian EM, Barkis WB, Chen S, Diamond JS, Barres BA. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci. 2004;26:544–57.CrossRefPubMed
46.
Russo R, Rotiroti D, Tassorelli C, et al. Identification of novel pharmacological targets to minimize excitotoxic retinal damage. Int Rev Neurobiol. 2009;85:407–23.CrossRefPubMed
47.
Inoue-Matsuhisa E, Sogo S, Mizota A, Taniai M, Takenaka H, Mano T. Effect of MCI-9042, a 5-HT2 receptor antagonist, on retinal ganglion cell death and retinal ischemia. Exp Eye Res. 2003;76:445–52.CrossRefPubMed
48.
Lingor P, Koeberle P, Kügler S, Bähr M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain. 2005;128:550–8.CrossRefPubMed
49.
Osborne NN, Lascaratos G, Bron AJ, Chidlow G, Wood JP. A hypothesis to suggest that light is a risk factor in glaucoma and the mitochondrial optic neuropathies. Br J Ophthalmol. 2006;90:237–41.CrossRefPubMedPubMedCentral
50.
Aronica E, Gorter JA, Ijlst-Keizers H, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci. 2003;17:2106–18.CrossRefPubMed
51.
Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci. 2000;41:1940–4.PubMed
52.
53.
Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun. 2001;286:433–42.CrossRefPubMed
54.
Wax MB, Yang J, Tezel G, Peng G, Patil RV, Calkins DJ. A model of experimental autoimmune glaucoma in rats elicited by immunization with heat shock protein27. Invest Ophthalmol Vis Sci 2002; 43 [E-abstract 2884].
55.
Tezel G, Hernandez MR, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol. 2000;118:511–8.CrossRefPubMed
56.
Joachim SC, Pfeiffer N, Grus FH. Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol. 2005;243:817–23.CrossRefPubMed
57.
Grus FH, Joachim SC, Hoffmann EM, Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol Vis. 2004;10:132–7.PubMed
58.
Grus FH, Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Wax MB. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci. 2006;47:968–76.CrossRefPubMed
59.
Yang J, Tezel G, Patil RV, Romano C, Wax MB. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci. 2001;42:1273–6.PubMed
60.
Yano T, Yamada K, Kimura A, et al. Autoimmunity against neurofilament protein and its possible association with HLA-DRB1*1502 allele in glaucoma. Immunol Lett. 2005;100:164–9.CrossRefPubMed
61.
Grus FH, Joachim SC, Wuenschig D, Rieck J, Pfeiffer N. Autoimmunity and glaucoma. J Glaucoma. 2008;17:79–84.CrossRefPubMed
62.
Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666–73.CrossRefPubMed
63.
64.
Yuan L, Neufeld AH. Tumor necrosis factor-α: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42–50.CrossRefPubMed
65.
Luo C, Yang X, Powell DW, Klein JB, Tezel G. Stress proteins and immunostimulatory signaling through toll-like receptors in glaucoma. Invest Ophthalmol Vis Sci 2009; 50 [E-abstract 4048].
66.
67.
Oldstone MB. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol. 2005;296:1–17.PubMed
68.
Galloway PH, Warner SJ, Morshed MG, Mikelberg FS. Helicobacter pylori infection and the risk for open-angle glaucoma. Ophthalmology. 2003;110:922–5.CrossRefPubMed
69.
Kountouras J, Zavos C, Chatzopoulos D. Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Med Hypoth. 2004;62:378–81.CrossRef
70.
Kim JM, Kim SH, Park KH, Han SY, Shim HS. Investigation of the association between Helicobacter pylori infection and normal tension glaucoma. Invest Ophthalmol Vis Sci. 2011;52:665–8.CrossRefPubMed
71.
Shokoohi KK, Shin DH, Elliott D, et al. Antiphospholipid antibodies in patients with normal tension glaucoma. Invest Ophthalmol Vis Sci. 1999;40(Suppl):342.
72.
Kremmer S, Kreuzfelder E, Klein R, Bontke N, Henneberg-Quester KB, Steuhl KP, Grosse-Wilde H. Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin Exp Immunol. 2001;125:211–5.CrossRefPubMedPubMedCentral
73.
Bachor E, Kremmer S, Kreuzfelder E, Jahnke K, Seidahmadi S. Antiphospholipid antibodies in patients with sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2005;262:622–6.CrossRefPubMed
74.
75.
Gloor BP, Sarra GM. Visusverlust und Sehstörung (2. Teil). Schweiz Med Forum. 2004;4:308–12.
76.
Medeiros FA, Vizzeri G, Zangwill LM, Alencar LM, Sample PA, Weinreb RN. Comparison of retinal nerve fiber layer and optic disc imaging for diagnosing glaucoma in patients suspected of having the disease. Ophthalmology. 2008;115:1340–6.CrossRefPubMedPubMedCentral
77.
Chauhan BC, O’Leary N, Almobarak FA, et al. Enhanced detection of open-angle glaucoma with an anatomically accurate optical coherence tomography-derived neuroretinal rim parameter. Ophthalmology. 2013;120:535–43.CrossRefPubMed
78.
79.
80.
Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99:635–49.CrossRefPubMed
81.
O’Neill EC, Danesh-Meyer HV, Kong GX, et al. Optic disc evaluation in optic neuropathies: the optic disc assessment project. Ophthalmology. 2011;118:964–70.CrossRefPubMed
82.
Hutchinson JK, et al. Optic neuropathies: glaucomatous vs. non-glaucomatous. 18th annual glaucoma report. Rev Optom. 2012;149:58.
83.
Moster ML, Kay MD. Glaucoma: the neuro-ophthalmologic differential diagnosis. J Curr Glaucoma Pract. 2008;2:33–8.CrossRef
84.
Trobe JD, Glaser JS, Cassady JC. Optic atrophy. Differential diagnosis by fundus observation alone. Arch Ophthalmol. 1980;98:1040–5.CrossRefPubMed
85.
CNTGSG. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–97.CrossRef
86.
CNTGSG. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.CrossRef
87.
88.
89.
Mozaffarieh M, Flammer J. Is there more to glaucoma treatment than lowering IOP? Surv Ophthalmol. 2007;52:S174–9.CrossRefPubMed
90.
Mackenzie P, Cioffi G. How does lowering of intraocular pressure protect the optic nerve? Surv Ophthalmol. 2008;53:S39–43.CrossRefPubMed
91.
Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J Pediatr Ophthalmol Strabismus. 2001;5:281–4.CrossRef
92.
Schuettauf F, Quinto K, Naskar R, Zurakowski D. Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vis Res. 2002;42:2333–7.CrossRefPubMed
93.
Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Bohres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 Study. Arch Ophthalmol. 2001;119:191–6.PubMed
94.
95.
Nucci C, Bari M, Spano A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 2008;173:451–64.CrossRefPubMed
96.
Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol. 2001;45:S284–9 (discussion S295–6).CrossRefPubMed
97.
Pang IH, Johnson EC, Jia L, Cepurna WO, Shepard AR, Hellberg MR, Clark AF, Morrison JC. Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Invest Ophthalmol Vis Sci. 2005;46:1313–21.CrossRefPubMed
98.
Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379–90.CrossRefPubMedPubMedCentral
99.
100.
Bell K, Gramlich OW, Von Thun Und Hohenstein-Blaul N, Beck S, Funke S, Wilding C, Pfeiffer N, Grus FH. Does autoimmunity play a part in the pathogenesis of glaucoma? Prog Retin Eye Res. 2013;36:199–216.CrossRefPubMed
101.
102.
Read RW, et al. Nongranulomatous inflammation: uveitis, endophthalmitis, panophthalmitis, and sequelae. In: Tasman W, et al., editors. Duane’s clinical ophthalmology. Baltimore: Lippincott Williams & Wilkins; 2004.
Metadata
Title
Glaucoma: recent advances in the involvement of autoimmunity
Authors
Maria Ida Rizzo
Antonio Greco
Armando De Virgilio
Andrea Gallo
Luciano Taverniti
Massimo Fusconi
Michela Conte
Giulio Pagliuca
Rosaria Turchetta
Marco de Vincentiis
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8837-3

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue

Therapeutic Aspects in Autoimmunity

On the pathogenesis of insulin-dependent diabetes mellitus: the role of microbiota

Mechanism in Autoimmunity

The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test

Environment and Autoimmunity

Is the immune neuroendocrine system the connection between epipharyngitis and chronic fatigue syndrome induced by HPV vaccine?

Environment and Autoimmunity

Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature

Environment and Autoimmunity

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

Environment and Autoimmunity

Phospholipid supplementation can attenuate vaccine-induced depressive-like behavior in mice